Genmab A (GMAB) Total Liabilities (2019 - 2026)

Genmab A has reported Total Liabilities for 6 years, with the latest figure at $6.7 billion in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities fell 4.73% year-over-year to $6.7 billion; the trailing twelve-month figure through Mar 2026 stood at $6.7 billion (down 4.73% YoY), and the FY2025 full-year result was $7.0 billion, up 450.2% from the prior year.
• Total Liabilities for Q1 2026 stood at $6.7 billion, down from $7.0 billion in the prior quarter.
• The five-year high for Total Liabilities was $7.0 billion in Q1 2025, with the low at -$5.1 billion in Q1 2024.
• Historically, Total Liabilities has averaged $2.3 billion across 4 years, with a median of $1.3 billion in 2025.
• Annual changes were most pronounced in 2025 — Total Liabilities jumped 450.2% — and 2026, when it retreated 4.73%.
• Genmab A's Total Liabilities stood at $545.0 million in 2023, then jumped by 134.31% to $1.3 billion in 2024, then jumped by 450.2% to $7.0 billion in 2025, then dropped by 4.73% to $6.7 billion in 2026.
• The last three Total Liabilities figures came in at $6.7 billion (Q1 2026), $7.0 billion (Q4 2025), and $1.3 billion (Q3 2025), per Business Quant data.